Does Ozempic & Wegovy Cause Intestinal Obstruction? A Doctor Explains

A Scary Headline That Deserves a Calm Explanation

If you have searched for side effects of GLP-1 medications, you have probably seen alarming headlines about intestinal obstruction. The idea that a weight loss medication could cause a bowel blockage is genuinely frightening, and it is the kind of story that gets amplified quickly on social media. Dr. Jen Caudle, a board-certified family medicine physician, takes on this topic with the measured approach it requires, explaining what we actually know versus what the fear-driven coverage implies.

The background here matters. In 2023, several case reports and a pharmacovigilance database analysis flagged a potential signal for intestinal obstruction (also called bowel obstruction or ileus) among patients using semaglutide and other GLP-1 receptor agonists. These reports made national news and triggered understandable anxiety among millions of people taking or considering these medications. But a signal in a pharmacovigilance database is not the same thing as a confirmed causal relationship, and Dr. Caudle walks through that distinction clearly.

How GLP-1 Medications Affect Your Gut

To understand the intestinal obstruction concern, you need to understand how GLP-1 receptor agonists interact with your digestive system. These drugs work partly by slowing gastric emptying, which means food stays in your stomach longer than it normally would. This is one of the mechanisms that produces the feeling of fullness and reduced appetite that makes these medications effective for weight loss.

Slowing gastric emptying is a feature, not a bug. Your body naturally releases GLP-1 when you eat, and one of its natural functions is to slow digestion so nutrients are absorbed more gradually. GLP-1 medications amplify this natural process. The result is that food moves through your upper digestive tract more slowly, which is why nausea and constipation are among the most common side effects reported by patients.

The concern about intestinal obstruction relates to whether this slowing effect could, in rare cases, become severe enough to cause a true blockage. An intestinal obstruction occurs when the passage of food and digestive material through the intestines is physically blocked, either by a mechanical cause (like scar tissue, a tumor, or a hernia) or by a functional cause (where the intestinal muscles stop contracting effectively, called an ileus).

What the Data Actually Shows

Dr. Caudle reviews the available evidence and makes several important points. First, the pharmacovigilance data that generated the headlines came from the FDA Adverse Event Reporting System (FAERS), which is a voluntary reporting database. Anyone can submit a report, and the reports do not establish causation. They identify signals that warrant further investigation. The fact that intestinal obstruction reports appeared more frequently among GLP-1 users than among users of some other medications was notable, but it needed context.

That context includes the fact that millions of people are now taking GLP-1 medications, and the patient population skews heavily toward people with obesity, who already have higher baseline rates of certain gastrointestinal conditions. Obesity itself is a risk factor for intestinal issues, including hernias that can cause mechanical obstruction. Disentangling the medication effect from the underlying population risk is challenging with pharmacovigilance data alone.

Second, the actual rate of reported intestinal obstruction events is very low in absolute terms. Even in the analyses that showed a statistically significant signal, the incidence was measured in single-digit cases per tens of thousands of patients. For comparison, the rate of intestinal obstruction in the general adult population is approximately 3-5 per 10,000 people per year, and many of the cases reported in GLP-1 users may have occurred at similar background rates.

The Difference Between Slowed Motility and True Obstruction

Dr. Caudle makes a critical clinical distinction that many news reports missed. Slowed gastrointestinal motility, which is common on GLP-1 medications, is not the same thing as intestinal obstruction. Feeling bloated, having delayed digestion, or experiencing constipation are uncomfortable but not dangerous in the vast majority of cases. A true obstruction is a medical emergency that causes severe pain, vomiting, inability to pass gas or stool, and potentially life-threatening complications if untreated.

The symptoms exist on a spectrum. Mild motility slowing causes occasional bloating and constipation. Moderate slowing might cause significant discomfort and require dose adjustment or temporary medication discontinuation. Severe motility failure (ileus) is rare and usually occurs in the context of other risk factors like recent surgery, opioid use, severe electrolyte imbalances, or pre-existing bowel conditions.

Most of the case reports linked to GLP-1 medications describe ileus (functional obstruction due to decreased intestinal muscle activity) rather than mechanical obstruction (physical blockage). This distinction matters because ileus is typically reversible with conservative treatment, while mechanical obstruction may require surgery. It also matters because ileus is a known potential consequence of anything that significantly slows gut motility, including opioid medications that are far more commonly associated with this complication.

Risk Factors to Watch For

Dr. Caudle identifies several factors that may increase the risk of serious gastrointestinal complications on GLP-1 therapy. Previous abdominal surgery creates scar tissue (adhesions) that can serve as points where an obstruction is more likely to develop. A history of bowel obstruction from any cause increases the risk of recurrence. Concurrent use of opioid pain medications, which also slow gut motility, can compound the slowing effect of GLP-1 drugs. Severe constipation that is not managed can theoretically progress to more serious obstruction in rare cases.

If you have any of these risk factors, it does not mean you cannot use GLP-1 medications. It means your prescribing physician should be aware of them so they can monitor you appropriately and adjust treatment if significant gastrointestinal symptoms develop.

What You Should Actually Worry About (And What You Should Not)

The honest assessment, which Dr. Caudle delivers well, is that intestinal obstruction is a very rare potential complication that should be on your awareness radar but should not prevent you from considering GLP-1 therapy if you are otherwise a good candidate. The far more common gastrointestinal side effects, nausea, constipation, diarrhea, and bloating, affect a much larger percentage of users and are the issues you are more likely to need to manage.

Managing these common GI side effects proactively can also reduce whatever small risk exists for more serious complications. Staying well hydrated, eating adequate fiber, maintaining physical activity, and using stool softeners when needed all support healthy gut motility. Starting GLP-1 medications at the lowest dose and titrating up slowly, as most prescribing protocols recommend, gives your digestive system time to adapt to the slowed gastric emptying.

If you experience severe abdominal pain, persistent vomiting (especially if you cannot keep fluids down), complete inability to pass gas or have a bowel movement for more than 3-4 days, or abdominal distension that is getting progressively worse, seek medical attention. These are warning signs of potential obstruction regardless of what medications you take, and they should never be ignored or attributed to "just a side effect" without medical evaluation.

The Anesthesia Connection

One practical concern that Dr. Caudle touches on is the implication of slowed gastric emptying for surgical patients. If you are scheduled for surgery that requires general anesthesia, your anesthesiologist needs to know you are taking a GLP-1 medication. Slowed gastric emptying means your stomach may contain food or liquid even after fasting, which increases the risk of aspiration (inhaling stomach contents into the lungs) during anesthesia.

Current guidelines from the American Society of Anesthesiologists recommend holding GLP-1 medications before elective surgery. The specific timing varies by drug and formulation: daily GLP-1 drugs may need to be held for 24 hours, while weekly injections like semaglutide may need to be held for a week or more before surgery. This is not about the obstruction risk per se. It is about making sure your stomach is truly empty before you are put under anesthesia.

Putting This in Perspective

Every effective medication carries some risk. Ibuprofen can cause stomach ulcers. Acetaminophen can damage the liver. Statins can cause muscle pain. The question is never whether a drug has potential side effects (they all do) but whether the benefits outweigh the risks for a given patient. For the vast majority of people who are candidates for GLP-1 therapy, the metabolic benefits of significant weight loss far outweigh the very small risk of serious gastrointestinal complications.

Dr. Caudle's video is a useful counterweight to the sensational headlines. She does not dismiss the concern. She contextualizes it. She explains the difference between common GI side effects and rare serious complications, identifies risk factors that warrant extra caution, and provides practical guidance for recognizing when symptoms need medical attention. That is exactly the kind of information people need when deciding whether to start or continue GLP-1 therapy.

If you are currently taking a GLP-1 medication and experiencing GI symptoms, talk to your prescribing physician. Most GI side effects can be managed with dose adjustments, dietary changes, and supportive measures. If you are avoiding GLP-1 therapy entirely because of obstruction fears, this video may help you have a more informed conversation about the actual level of risk involved.